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Upon cell infection, some viruses integrate their genome into the host chromosome, either as part of 
their life cycle (such as retroviruses), or incidentally. While possibly promoting long-term persistence of 
the virus into the cell, viral genome integration may also lead to drastic consequences for the host cell, 
including gene disruption, insertional mutagenesis and cell death, as well as contributing to species 
evolution. This review summarizes the current knowledge on viruses integrating their genome into the 



















Upon host infection, viruses hijack multiple cellular functions in order to promote their replication and 
favor viral particle progeny. To ensure this, some viruses evolved the ability to integrate their genome 
into the host chromosomes, yielding to various consequences for the host cell, including gene 
disruption, oncogenesis or premature cell death, and may ultimately contribute to species evolution 
through inheritable genome inclusions. Although viral genome integration into the host genome is an 
obligatory step for viruses such as retroviruses, it may also occur incidentally for some viruses (Table 
1). This review will summarize the current knowledge on viruses integrating into the host genome and 
the consequences for the host cell.  
 
1. RNA viruses 
By definition, RNA viruses are not able to integrate their genome into the host chromosome, as their 
genetic information resides in RNA molecules and not DNA. The only exception to this are 
retroviruses, which are characterized by the reverse transcription of their viral RNA genome into a 
linear double-strand DNA molecule (viral DNA intermediate), and thus the substrate for subsequent 
viral genome integration into the host genome. For retroviruses, integration is a mandatory step for 
productive infection. Apart from retroviruses, the genome of other RNA viruses has been recently 
identified in the host genome. However, in these cases, integration seems to have occurred 
incidentally, as demonstrated for lymphocytic choriomeningitis virus (LCMV), an arenavirus. This 
section will cover the integration process of retroviruses including endogenous retroviruses and the 
incidental integration of LCMV.  
 
1.1. Retroviruses 
The life cycle of retroviruses can be divided in several crucial steps (Figure 1-A): viral entry through 
host cell-specific receptors dictating viral tropism, core penetration, uncoating, reverse transcription of 
the viral RNA genome, nuclear translocation and integration of the viral cDNA genome into the host 
chromosomes, transcription of the integrated provirus*, translation, virion assembly, budding and 
release Friedrich et al. (2011).  
Viral genome integration into the host genome is a hallmark of retroviruses, as it is a mandatory step 
in the retroviral life cycle and a prerequisite for productive infection. Upon integration, the retrovirus will 
persist in the infected cell for its entire lifespan, and will affect host gene expression depending on the 
integration site. Furthermore, if retroviral infection and integration occurs in the germline, the provirus 
will be transmitted to the progeny, and will thus contribute shaping the genome of future generations. 
This is the case of the so called “endogenized” retroviruses or endogenous retroviruses (ERV).  
 
1.1.1. Integration mechanism 
After reverse transcription, the linear double stranded cDNA flanked by the long terminal repeats 
(LTR) is completed and part of a nucleoprotein complex called preintegration complex (PIC). The PIC 
contains multiple viral and cellular proteins - including viral integrase (IN), matrix (MA), Vpr, and 
cellular barrier-to-autointegration factor (BAF), high-mobility group chromosomal protein A1 (HMGA1), 
integrase interactor 1 (Ini1), lens epithelium-derived growth factor (LEDGF/p75) for HIV - that may 
contribute to nuclear translocation, integration of the viral genome, and subsequent immediate 
transcription, and which composition may vary along the way to the host genome (Belshan et al., 
2009, Farnet and Haseltine, 1991, Fassati and Goff, 2001, Lin and Engelman, 2003, Miller et al., 
1997, Raghavendra et al., 2010). To cross the nuclear membrane and reach the nucleus, retroviruses 
have evolved different strategies. Simple retroviruses (alpharetroviruses, betaretroviruses, 
gammaretroviruses and epsilonretroviruses) are able to reach the nucleus only upon nuclear 
membrane disruption occurring at the time of mitosis, providing a coherent explanation on why these 
retroviruses infect dividing cells but are unable to infect non-dividing cells (Lewis and Emerman, 1994, 
Roe et al., 1993). In contrast, spumaviruses and lentiviruses have the capacity to infect both dividing 
and non-dividing cells, entering the nucleus through an active, yet poorly elucidated, mechanism 
(Suzuki and Craigie, 2007). The current model for HIV proposes that a PIC containing minimally the 
viral integrase and the viral cDNA crosses the nuclear membrane through the nuclear pore complex 
*Provirus: integrated genome sequence of a virus. 
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(NPC), a superstructure mediating the transport of macromolecules between the cytoplasm and the 
nucleus, via specific interactions with NPC proteins, including importin α3, importin 7, NUP153, 
RANBP2 and Transportin-SR2/TNPO3 (Ao et al., 2010, Christ et al., 2008, Levin et al., 2010).  
Retroviral genome integration occurs in three steps, the first two being catalyzed by the retroviral 
integrase (IN) protein (figure 1-B, the example of HIV) (Li et al., 2011). IN is bound to the LTR and 
requires approximately the 32 terminal nucleotides (Bera et al., 2009). First, when the PIC is still in the 
cytoplasm (Miller et al., 1997), IN hydrolyzes a dinucleotide at each 3’ end, a process called 3’ 
processing. Second, IN catalyzes the strand transfer reaction, consisting in simultaneously breaking 
the host DNA asymmetrically and joining it to the recessed viral DNA 3’-OH ends. The IN-mediated 
asymmetric DNA breaks in the host genome are determined by the viral protein structure and vary 
between 4 to 6 nucleotides. Finally, to stabilize the proviral insertion, the host DNA repair machinery – 
involving the DNA-dependent kinase (DNA-PK) comprising a DNA-PK catalytic subunit and a DNA 
binding Ku80/Ku70 complex, and the ligase IV/XRRC4 complex of the non-homologous end joining 
pathway (NHEJ) - cleaves the viral protruding 5’ nucleotides and fills in the 4-6 bp gap, resulting in the 
duplication of the gap nucleotide sequence surrounding the provirus.  
The retroviral IN enzyme belongs to the family of polynucleotidyl transferases. It contains between 280 
and 450 amino acids depending on the retrovirus (for example, HIV-1 IN: 288 amino acids), that are 
divided in three protein domains (Li et al., 2011). The N-terminal domain (residues 1-50 in HIV-1 IN), 
containing an HHCC zinc-binding motif, is involved mostly in viral DNA binding, and IN 
multimerization. The C-terminal domain (residues 212-288 in HIV-1 IN) is also involved in DNA binding 
and IN multimerization. And most importantly, the catalytic core domain (residues 50-212 in HIV-1 IN), 
carrying a typical signature with the D,D(35)E acidic triad in the active site, is essential for metal 
(Mg2+) binding and IN enzymatic activity, and is involved in viral DNA binding as well as host cellular 
target DNA binding. The catalytic core domain has also been shown to contribute to IN 
multimerization. 
In vitro, purified recombinant IN alone is able to perform 3’ processing and strand transfer. Initial 
experiments showed that IN was able to catalyze half site integration (one LTR end integrated in the 
acceptor DNA) using 21-mer oligonucleotides mimicking the U3 or U5 ends of the LTR. However, the 
use of longer DNA substrates mixed with IN allowed to reconstitute concerted full-site integration 
(integration of both LTR ends) (Sinha and Grandgenett, 2005, Sinha et al., 2002), thereby mimicking 
the in vivo situation more faithfully and suggesting that other genomic regions in addition to LTR 
extremities contribute to integration efficiency (Li and Craigie, 2005). Although IN is sufficient to 
perform the first two steps of integration in vitro, multiple PIC components, including LEDGF/p75,  
were shown to improve the efficiency of this process, both in vitro and in vivo (Van Maele et al., 2006). 
The current and commonly accepted model, supported by crystallography, implies that IN activity is 
linked to its oligomeric state: IN dimers bound to LTR termini catalyze the 3’ processing whereas 
concerted integration requires IN tetramers (Diamond and Bushman, 2005, Faure et al., 2005, Delelis 
et al., 2007, Guiot et al., 2006, Jaskolski et al., 2009, Cherepanov et al., 2011, Hare et al., 2010).  
 
1.1.2. Integration site selection  
As mentioned in the previous section, purified IN alone is able to catalyze the first two steps of 
integration in vitro at any phosphodiester bond of the DNA target, suggesting that IN does not have 
any DNA sequence preference at the level of the DNA recipient molecule. 
However, a pioneering study by Schröder et al (2002) took advantage of the published human 
genome sequence and showed that in vivo, the sites of HIV-1 integration were not random but rather 
favored specific chromosomal features, such as transcription units (Schroder et al., 2002). Since then 
and thanks to the appearance of high-throughput sequencing technologies and the availability of the 
genomic sequence of multiple species, a more complete picture of retroviral integration preferences 
emerged (Figure 2-A) (Bushman et al., 2005, Ciuffi and Bushman, 2006, Lewinski et al., 2005, 
Lewinski and Bushman, 2005, Delelis et al., 2010, Desfarges and Ciuffi, 2010).  
All retroviruses do not display the same integration site preferences. Indeed gammaretroviruses, 
spumaretroviruses and endogenous retroviruses favor promoters and transcription start sites of active 
genes, characterized by high CpG islands and DNaseI hypersensitive sites (Mitchell et al., 2004, Wu 
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et al., 2003, Trobridge et al., 2006, Brady et al., 2009, Kim et al., 2008, Kim et al., 2011). Integration of 
alpharetroviruses and deltaretrovirues is also, although weakly, favored in transcription units and CpG 
islands (Derse et al., 2007, Mitchell et al., 2004). In contrast, lentiviruses prefer integrating in active 
genes, along the transcription unit, in both introns and exons, and are often associated with epigenetic 
marks associated with active transcription, including H3Ac, H4Ac, H3K4me3, H3K36me3, while 
disfavoring epigenetic marks associated with repressed transcription such as H3K9me3, H3K27me3, 
H3K79me3, H4K20me3 and DNA methylation (Brady et al., 2011, Derse et al., 2007, Mitchell et al., 
2004, Roth et al., 2011, Schroder et al., 2002, Wang et al., 2007, Wang et al., 2009). Finally, the 
MMTV betaretrovirus is the only one considered to integrate randomly, with no statistically significant 
preference for chromosomal features (Faschinger et al., 2008), nevertheless some common 
integration sites near cellular oncogenes belonging to Wnt and Fgf families have been reported 
(Callahan and Smith, 2000, Callahan and Smith, 2008).  
Although no DNA consensus sequence was identified in vitro, a weak DNA consensus appears in vivo 
at the host insertion site as well as surrounding the integration site. Furthermore, in the case of HIV-1, 
a specific nucleosomal DNA architecture, i.e. the outward-facing major groove of the target DNA 
(possibly consistent with the weak consensus DNA sequence), is favored for integration, presumably 
due to IN protein structure constraints (Wang et al., 2007). 
To date, many hypotheses have been imagined to explain this retroviral-specific integration site 
selection, including the role of cell cycle, chromatin accessibility and tethering proteins. Although all 
these models may contribute to integration site selection, only evidence for the tethering model has 
been identified so far (Figure 2-B). This model suggests that integration site selection is dictated by a 
protein, directly or indirectly complexed with the retroviral-specific IN, and acting as a tethering protein 
between the PIC and the host chromatin, thereby promoting integration at a nearby DNA site 
(Bushman et al., 2005, Ciuffi and Bushman, 2006, Desfarges and Ciuffi, 2010). Therefore, any PIC 
component could potentially act as a tethering protein. 
Three major lines of evidence argue in favor of this tethering model. The first one takes advantage of 
chimeric constructs between MLV and HIV, and the subsequent analysis of integration site distribution 
(Lewinski et al., 2006). Swaps between HIV and MLV at the level of Gag and IN highlighted the role of 
these two viral proteins as major determinants for integration targeting. Indeed, HIV vector containing 
MLV Gag only displayed specific integration preferences that differed from both HIV and MLV and 
suggesting that Gag may play a role in integration site selection. In contrast, HIV vector containing 
MLV IN lost integration preferences for transcription units and acquired preferences for transcription 
start sites close to MLV phenotype, suggesting that HIV IN is the major determinant for HIV integration 
site selection. However, an HIV vector containing both MLV Gag and MLV IN preferentially integrated 
into transcription start sites, completely recapitulating MLV integration site distribution, thereby 
suggesting that in the case of MLV, both Gag and IN are likely to be major viral determinants of 
integration site selection.  
The second line of evidence resides in the identification of the HIV IN-interacting protein, LEDGF/p75, 
that was shown to play a key role in integration efficiency as well as integration site distribution 
(Cherepanov et al., 2005a, Cherepanov et al., 2005b, Ciuffi et al., 2005, Engelman and Cherepanov, 
2008, Llano et al., 2006, Marshall et al., 2007, Poeschla, 2008), thereby providing the proof-of-concept 
that LEDGF/p75 is acting as the major tethering protein for the HIV PIC. Indeed, cells depleted for 
LEDGF/p75 do not favor transcription units anymore but rather CpG islands (Ciuffi et al., 2005, 
Marshall et al., 2007, Schrijvers et al., 2012, Shun et al., 2007). LEDGF/p75 is required for efficient 
integration and site selection, not only for HIV, but for many lentiviruses (SIV, EIAV) (Busschots et al., 
2007, Cherepanov, 2007, Marshall et al., 2007). In contrast, integration site selection of other 
retroviruses, such as MLV (a gammaretrovirus), is not affected by LEDGF/p75 depletion, providing 
additional evidence that LEDGF/p75 is the major tethering factor for lentiviruses only. Of note, 
Schrijvers et al recently demonstrated that, in absence of LEDGF/p75, hepatoma-derived growth 
factor related protein 2 (HRP2) was acting as an alternative tethering protein for HIV PIC, although 
less efficient than LEDGF/p75 (Schrijvers et al., 2012). Except for Foamy virus (FV), for which 
H2A/H2B heterodimers were shown to interact with FV Gag, thus tethering FV PIC to chromatin 
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(Tobaly-Tapiero et al., 2008), specific tethering proteins for other retroviral genera remains to be 
identified.  
The third line of evidence originates from experiments using LEDGF/p75 chimera, in which the 
chromatin binding domain of LEDGF/p75 was substituted with the one of other chromatin binding 
proteins, including the phage λ repressor protein, H1 histone, KSHV latency-associated nuclear 
antigen, heterochromatin protein 1-α, inhibitor of growth protein 2 and heterochromatin protein 1-β 
(Ciuffi et al., 2006, Ferris et al., 2010, Gijsbers et al., 2010, Gijsbers et al., 2011, Meehan and 
Poeschla, 2010, Meehan et al., 2009, Silvers et al., 2010). All these studies showed that, by changing 
the chromatin binding of LEDGF/p75, integration site selection can be redirected from transcription 
units to new preferential host chromatin sites, dictated by the chromatin binding specificity of the 
chimeric protein, These data confirm the role of LEDGF/p75 in HIV integration site selection and 
suggest that integration targeting can be modulated, a feature of great interest for gene therapy 
studies involving retroviral-based vectors. 
Although tethering appears so far to be a major mechanism involved in integration site selection, 
recent studies demonstrated that integration targeting could also be affected by nuclear import. 
Indeed, it has been shown that depletion of nuclear pore proteins, such as Transportin-3/TNPO3 or 
RanBP2/Nup358 resulted in the reduction of HIV integration events in gene dense regions, but has no 
effect on MLV integration distribution (consistent with the concept that MLV does not enter the nucleus 
through the nuclear pore). These data provide evidence of a functional coupling between HIV nuclear 
import and integration, implying a role for proper nuclear trafficking of HIV complexes in integration site 
distribution (Ocwieja et al., 2011, Schaller et al., 2011). 
 
1.2.  Incidental integration of non-retroviral RNA viruses. 
As mentioned at the beginning of this section, RNA viruses normally do not integrate. However, the 
genomic sequence of lymphocytic choriomeningitis virus (LCMV), an arenavirus, has been identified in 
genome of infected mice and is seemingly the result of an incidental event that will be described 
hereafter. 
Arenaviruses are the etiologic agents of hemorrhagic fever disease in humans. Arenaviruses are 
enveloped viruses containing a bisegmented negative single stranded RNA genome coding for four 
viral proteins: an RNA-dependent RNA polymerase, the nucleocapsid, the glycoprotein and a RING-
domain containing protein. The replication of arenaviruses is completely different from retroviruses, 
with a broader cell tropism (Emonet et al., 2011). Viral replication takes place exclusively in the 
cytoplasm in which RNA synthesis is performed by the virally encoded RNA-dependent RNA 
polymerase (RdRp). Although RdRps belong to the reverse transcriptase-like superfamily, no reverse 
transcriptase activity has been detected so far. Therefore, these viruses normally do not integrate into 
the host chromosomes. However, studies aiming at characterizing LCMV persistence in infected mice 
were able to detect LCMV DNA sequences by PCR in ~60% of mice 200 days post-infection (long 





(Klenerman et al., 1997). LCMV DNA was also detected in murine and hamster cell lines (which are 
considered as the natural hosts for LCMV), but not in non-natural host cell lines (human, monkey, dog, 
cow). Further analysis highlighted a role for retrotransposons*, encoding a reverse transcriptase, in the 
generation of LCMV DNA and subsequent integration. Interestingly, murine and hamster cells display 
a high level of endogenous RT activity, consistent, in part, with the natural host restriction observed. 
Recently, Geuking et al. showed that RT from endogenous retrotransposons can illegitimately 
recombine with the exogenous LCMV RNA genome by template switching, providing additional data 
pointing towards the role of retrotransposons in reverse transcribing and integrating LCMV genomic 
sequences (Geuking et al., 2009). 
Totiviridae and Partitiviridae are superfamilies containing a broad range of RNA viruses infecting fungi, 
protozoa, nematods, arthropods and plants. Similarly to arenaviruses, neither reverse transcriptase 
activity, nor integration activity have been reported for these viruses. However, sequences of the 
capsid and the RdRp genes have been identified in many eukaryotic genomes, suggesting that 
integration of these viral sequences can occur more frequently as initially expected (Liu et al., 2010). 
Based on these observations, the question remains: how can these viral sequences integrate in the 
*Retrotransposons are mobile genetic DNA elements that resemble retroviruses, with reverse transcription and integrase 
activities but devoid of the extracellular part of the life cycle.  
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host genome? Liu and coworkers proposed two models: (i) an illegitimate and incidental recombination 
with retrotransposons may occur, leading to the integration of viral sequences, as described for LCMV 
(Geuking et al., 2009, Tanne and Sela, 2005) or (ii) the double-strand-break repair machinery of the 
host cell may capture nearby viral DNA sequences and insert them in some instable regions of the 
genome, as described in yeast (Frank and Wolfe, 2009, Puchta, 2005). Although both models can 
each contribute, only the first model enacting a role for retrotransposons can explain the prior 
appearance of a viral DNA intermediate, essential for being considered as a substrate of host genome 
insertion. 
 
2. DNA viruses 
Unlike RNA viruses, the genome of DNA viruses is already a potential substrate for host genome 
integration, without the need for prior processing. In general, the genome of DNA viruses is 
translocated to the nucleus, where it remains as an episome to ensure viral persistence. However, the 
genome of some DNA viruses can be found inserted in the host genome. The mechanisms underlying 
these integration events, incidental or non-incidental, are still poorly characterized, and the potential 
advantages for these DNA viruses to integrate are still obscure. Understanding these mechanisms 
should help elucidate the role of DNA virus integration in the viral life cycle. This section will 
summarize the current knowledge on integration of some prototypic DNA viruses as well as 
highlighting some mechanisms involved in this process.  
 
2.1. Adeno-Associated Virus type 2 (AAV-2) 
The adeno-associated virus AAV is a widespread virus classified among the parvoviridae family. The 
relationship between AAV and the host remains obscure due partially to the absence of associated 
pathology. Replication of AAV is strictly conditioned by the presence in the same infected cell of helper 
viruses such as adenoviruses, human papillomaviruses (HPV) or herpes simplex viruses (HSV). In 
absence of helper viruses, AAV integrates its genome in a site-specific way. The molecular 
mechanism involved in AAV integration has only been investigated for the type 2 serotype (AAV-2). 
The genome organization of AAV-2 consists of two major open reading frames coding for the non-
structural proteins Rep (Rep78, Rep68, Rep52 and Rep40) and structural proteins Cap (VP1, VP2 and 
VP3), flanked by inverted terminal repeats (ITR). The site-specific integration of AAV-2 is located in a 
non-repetitive element at the position 19q13,42 corresponding to the long arm of the chromosome 19, 
in a gene-dense region named AAVS1 (for AAV integration site 1) (Figure 3-A) (Kotin et al., 1991). 
Analysis of AAVS1 host sequence revealed two cis-acting sequences involved in AAV-2 integration: 
the terminal resolution site (TRS) corresponding to the Rep-specific endonuclease site and the Rep 
binding site (RBS) (Brister and Muzyczka, 1999, McCarty et al., 1994a, McCarty et al., 1994b). 
Interestingly, this TRS-RBS motif is also present in the ITR of the viral genome, suggesting that the 
sequence homology between AAV-2 ITR and the host genome site – TRS and RBS sequences – 
plays a role in AAV-2 integration. Recently, two new AAV-2 integration sites have been reported in 
chromosomes 5 (5p13.3) and 3 (3p24.3), named AAVS2 and AAVS3 respectively, that also carryi a 
RBS motif (Hüser et al., 2010). These data suggest. 
Biochemical characterization of the proteins Rep68 and Rep78 revealed several activities, including 
DNA binding, ATPase, helicase and endonuclease activities, essential to direct site-specific integration 
of AAV-2 genome (Surosky et al., 1997). All together, these data point to a molecular model of AAV-2 
integration in which the viral genome is tethered to a specific AAVS locus via concomitant binding of 
Rep68/78 on both cellular and viral RBS (Weitzman et al., 1994). More particularly, AAV-2 integration 
starts with Rep68/Rep78 complex introducing a nick at the adjacent cellular TRS that may induce the 
non homologous end-joining pathway (NHEJ) repair machinery. Non homologous recombination 
between the viral ITRs and the host DNA results in the viral insertion of AAV-2 in the host genome and 
the partial duplication of the integration site (Henckaerts and Linden, 2010, Lamartina et al., 2000, 
Urcelay et al., 1995). 
In conclusion, AAV long persistence, the absence of pathogenicity and the site-specific integration at 
AAVS loci render AAV a very attractive candidate for gene therapy. However, to date, nothing is 
known about the long-term effect of AAV integration at the AAVS locus, which is close to a gene-
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dense region, containing among others the myosin light chain phosphatase MBS85, an enzyme 
important for smooth muscle contraction. 
 
2.2. Herpes viruses 
Herpes viruses are DNA enveloped viruses, classified in three families based on their sequence 
phylogeny: α, β and γ herpes viruses. They contain a linear double stranded DNA that is delivered in 
the nucleus upon viral entry and circularized. It usually remains episomal, i.e. as an extrachromosomal 
circular DNA. However, some herpes viruses can integrate their genome into the host chromosomes, 
although these observations are considered as exceptions of the herpesvirus life cycle. In this part, we 
will highlight the features concerning integration of the γ-herpesvirus Epstein-Barr virus (EBV) and the 
β-herpesvirus Human Herpes Virus 6 (HHV-6) into the host chromosomes. 
 
2.2.1. Epstein-Barr virus (EBV) 
EBV is the prototypical member of the γ-herpesvirus family and is known to establish a long persistent 
infection in B-lymphocytes as well as in epithelial cells. EBV is associated with several proliferative 
disorders and cancers, including Burkitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal 
carcinoma (Epstein et al., 1964, Gutensohn and Cole, 1980, Zur Hausen and Schulte-Holthausen, 
1970). Two stages of EBV infection exist: (i) the lytic or productive cycle, in which the infected cell is 
actively releasing new infectious viral particles, and (ii) the latent cycle, in which only a few viral 
proteins are expressed, some of which are directly linked with cell proliferation and thus cancer. 
During latent infection, the EBV genome persists as an episome. However, the presence of linearized 
EBV genome in the host genome has been identified and confirmed using different approaches, 
including cytological hybridization, FISH, PCR, genomic library screening and sequencing. The 
presence of integrated EBV genome suggests an alternative way for EBV to establish long term 
infection (Gao et al., 2006, Hurley et al., 1991, Lestou et al., 1993). However, the question whether 
integration site selection occurs randomly or not is still a matter of debate, mainly due to the technical 
difficulties to isolate EBV integrations events from EBV episomes (Gao et al., 2006, Takakuwa et al., 
2004). Nevertheless, data so far suggest that EBV integration is not random and occurs preferentially 
in regions corresponding to heterochromatin (Gao et al., 2006, Lestou et al., 1993) (Figure 3-A). 
However, EBV integration has also been identified in genes, including MACF1, BACH-2 (putative 
tumor suppressor gene), REL and BCL-11A (proto-oncogenes), thereby revealing a potential impact of 
EBV integration in disrupting the expression of some cellular genes (Takakuwa et al., 2004). 
The EBV episome maintenance is ensured by the viral Epstein-Barr nuclear antigen 1 (EBNA-1) 
protein, attaching the episome to the host chromatin via AT hook motifs (Figure 3-B). The interaction 
of EBNA-1 with the cellular EBNA-1 Binding Protein 2 (EBP2) and high-mobility group protein 2 
(HMGB2) may also play a role in attaching the EBV episome to the host chromatin during interphase 
and mitosis (Jourdan et al., 2012). This chromatin attachment process could be enlarged to other 
family members, including the Kaposi ‘s sarcoma herpes virus (KSHV). Indeed, it was shown that 
KSHV episomal genome was attached to the host chromatin via the cellular histones 2A and 2B, the 
methyl-CpG-binding protein 2 (MeCP2) and the LANA (latency associated nuclear antigen) viral 
protein (Figure 3-B) (Barbera et al., 2006, Matsumura et al., 2010, Verma and Robertson, 2003). 
Although the mechanisms involved in EBV and KHSV genome integration into the host chromatin 
remains to be elucidated, it is tempting to hypothesize, based on the retroviral tethering model, that 
viral DNA episome integration requires initially these docking proteins (EBNA-1 complex, LANA 
complex), thereby creating an opportunity for the subsequent incidental recombination and insertion 
into the host DNA, probably mediated by the cellular DNA repair machinery.  
 
2.2.2. Human Herpes Virus-6 (HHV-6) 
HHV-6 is the causal agent of the roseola infantum occurring during the first years of life and 
characterized by an intense fever for a few days. After the primary infection, the virus is able to 
establish latency in some monocytes and macrophages. Viruses may be reactivated from latency, 
particularly in immunosuppressed patients, thereby causing secondary infections with severe 
complications such as encephalitis (Kondo et al., 1991, Kondo et al., 2002, Vu et al., 2007). 
8 
 
Integration of HHV-6 (also named chromosomally integrated human herpes virus 6, ciHHV-6) into the 
host chromosomes is well defined and remains one of the most consistent observations of DNA virus 
integration, with at least 34 published examples (Pellett et al., 2011). Although the molecular 
mechanism involved in this process is still not fully understood, a few hints are starting to emerge. 
The HHV-6 genome architecture is organized in two main regions: (i) the unique long region (UL) 
containing several gene blocks responsible for viral replication, and (ii) direct repeats (DR) flanking the 
genome. The right DR (DRR) and the left DR (DRL) contain a perfect [TAACCC]58 repeated sequence 
arrangement identical to the human telomeric repeat sequence, as well as an imperfect telomeric 
repeat sequence arrangement referred to the het region (Gompels and Macaulay, 1995). To date, all 
integration sites reported were localized in the telomeric regions with no preference for a given 
chromosome (Figure 3-A), suggesting that HHV-6 integrate its genome via homologous recombination 
between the viral and cellular telomeric sequences (Arbuckle et al., 2010, Nacheva et al., 2008). 
Recently, a role for the still poorly characterized HHV-6 U94 protein in HHV-6 integration was 
proposed, based on its strong homology with AAV-2 Rep68/78, particularly at the level of single-
stranded DNA binding activity (Dhepakson et al., 2002).  
The HHV-6 closely related Marek’s disease virus (MDV) was shown to have also viral telomeric 
sequences that facilitate MDV integration into host telomeres. Minimal changes in these sequences 
not only strongly reduced integration efficiency but also modified the integration site selection to 
regions outside the telomeres (Kaufer et al., 2011), providing additional evidence that the viral DR 
sequence is essential for integration targeting.  
 
2.3.  Hepatitis B Virus (HBV) 
The hepatitis B virus is one of the most common human pathogen responsible for the development of 
hepatocellular carcinoma (Neuveut et al., 2010). During acute infection, HBV can integrate its genome 
into the host chromosomes and present several similarities with retroviral integration. Although initial 
analyses of several HBV integration sites revealed random integration events in all chromosomes 
(Tokino and Matsubara, 1991, Yaginuma et al., 1987), a recent large-scale analysis identified favored 
HBV integration events in transcriptionally active regions (Murakami et al., 2005). Furthermore, HBV 
integration target genes (including hTERT, PDGF receptor, the mixed lineage leukemia 2 or the 60S 
ribosomal protein) were preferentially involved in cell proliferation, survival and oncogenesis (Ferber et 
al., 2003, Murakami et al., 2005, Tamori et al., 2005). Future studies are needed to further unveil the 
molecular mechanism of HBV integration the exact role of HBV integration in the establishment of 
hepatocellular carcinoma. 
 
2.4. Adenoviruses  
Adenoviruses are double stranded DNA viruses, usually perceived as non-integrating viruses with a 
genome persisting under episomal form. However, in hamster cells, the complete genome of Ad12 
was found to be stably integrated into the host chromosomes, with a few nucleotide modifications at 
the viral junctions. Similarly, Stephen et al. infected hamster immortalized (HT-1080 and C32) and 
primary fibroblasts (FF-92) with an Ad5-derived vector and identified 59 integration sites: 29 were 
found in active transcription units in all chromosomes and 15 out of the 30 integration sites identified 
outside genes were located near genes, suggesting preferential integration of Ad in gene loci (Figure 
3-A) (Stephen et al., 2010, Stephen et al., 2008). The current model suggests that Ad ITR contains 
specific SYREC (symmetric recombinant) sequences, which have stretches homologous to cellular 
repetitive elements, and that could thus allow Ad host genome insertion through patchy nucleotide 
homology (Figure 3-B) (Deuring and Doerfler, 1983, Deuring et al., 1981, Doerfler, 2009, Stabel and 
Doerfler, 1982, Wronka et al., 2002). Further analysis of Ad integration events in vitro and in vivo 
revealed that both homologous recombination and heterologous recombination (non homologous end 
joining pathway) were involved in this SYREC-mediated integration process (Hoglund et al., 1992, 
Stephen et al., 2010, Stephen et al., 2008, Wronka et al., 2002). Adenovirus-based vectors are 
currently the most used vectors in gene therapy, representing 24.2% of the clinical trials (source 
http://www.wiley.com//legacy/wileychi/genmed/clinical). Understanding the frequency and the 
9 
 
mechanisms of Ad integration and recombination should help render these vectors safer for gene 
therapy trials.  
 
3. Consequences of viral integration on the host cell 
The site of the viral integration event can have multiple consequences for the host, as well as for the 
virus itself. Indeed, viral integration can lead to cell death or proliferation as a result of insertional 
mutagenesis. However, integration can also lead to consequences for the virus, i.e. active production 
or transcriptional silencing, a process also called latency that is key to establish viral persistence. 
Finally, integration in the germline can contribute shaping the host genome and participate in species 
evolution. Each of these effects will be further discussed below. 
 
3.1. Cell death 
Apopotosis is a general mechanism involved in cell homeostasis regulation eliminating aberrant cells, 
with altered physiological parameters as well as a compromised genome integrity (Roulston et al., 
1999). Upon viral invasion, the presence of a linear double-stranded DNA is sensed by the host DNA 
repair machinery as a DNA break, which will lead to cell apoptosis unless successfully repaired 
(Daniel et al., 1999, O'Brien, 1998). Following the same concept, if the cell is invaded by multiple viral 
particles, thus multiple DNA genomes, it is likely that the DNA repair machinery will be overwhelmed, 
and will thus fail in repairing all the DNA molecules, thereby resulting in cell death. Similarly, if too 
many viral genomes integrate successfully, the integrity of the host genome itself may be 
compromised, also leading to cell death. In addition, viral integration will eventually lead to gene 
expression deregulation that may induce cell apoptosis. For instance, it has been reported that 
integration of HBV in SERCA-1 gene resulted in gene disruption and in the expression of a chimeric 
non functional protein HBVx/SERCA-1 (Figure 4). This chimeric protein lost calcium and ATP binding 
domains, thereby strongly disturbing the reticulum endoplasmic calcium homeostasis and inducing 
apoptosis (Chami et al., 2000). 
 
3.2. Tumorigenesis 
Many viruses have been characterized based on their ability to induce cellular transformation and thus 
tumors. However, two mechanisms of virus-induced cellular transformation should be distinguished.  
The first one leads to a rapid tumorigenesis process and is exemplified by oncoviruses, i.e. viruses 
coding for a viral oncogene and thus directly responsible for the cellular proliferation, such as some 
retroviruses (MMTV, MLV, RSV, HTLV) and DNA viruses (HPV, EBV, HBV, Ad) (Nevins, 2007). Of 
note, it has been suggested that Adenoviruses are more likely to induce cell death in permissive cells 
(including human cells), while inducing a tumor in non-permissive cells (hamster cells), often linked to 
Adenoviral genome integration (Doerfler, 2011, Doerfler, 2012). 
The second mechanism, which is directly related to viral integration, is called insertional mutagenesis. 
In this case, tumorigenesis is a slow process directly related to the viral integration site, which disturbs 
the cell homeostasis. Indeed, viral integration alters and modulates the expression of cellular nearby 
genes (Figure 4). A first scenario is the result of gene disruption by the viral integration event. If the 
disrupted gene is a tumor suppressor gene for example, this may ultimately lead to cellular 
transformation. Second, viral integration occurring close to cellular oncogenes may result in viral 
promoter-induced overexpression of the oncogene. The best illustration of this event occurred in a 
gene therapy trial aiming at correcting the severe combined immunodeficiency-X1 disease (SCID-X1) 
using a gammaretroviral vector providing a functional IL2RG gene (Cavazzana-Calvo et al., 2000). 
Although this trial was successful, restoring an immune function, 4 out of 9 patients developed 
leukemia in the five years following viral transduction (Hacein-Bey-Abina et al., 2008). The analysis of 
viral integration sites in the transduced cells identified integration events nearby the LMO2 proto-
oncogene, yielding to LMO2 overexpression (Hacein-Bey-Abina et al., 2008). The aberrant expression 
of LMO2 is a major determinant to T-cell immortalization as recently demonstrated in vitro after 
gammaretroviral transduction of the proto-oncogene LMO2 in T-cells (Newrzela et al., 2011). Although 
it was shown that MLV vectors preferentially integrate at promoters and regions close to the 
transcription start site (Kim et al., 2011, Kim et al., 2008, Mitchell et al., 2004, Wu et al., 2003), exon 1 
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of LMO2 locus was shown to be a hotspot for MLV integration in T cells, with 1 integration out of 5x10
4
 
(Yamada et al., 2009). Nonetheless, new MLV-derived vectors containing chromatin insulator 
elements from the chicken β-globin have been engineered to block the viral enhancer activity of the 
promoter, thereby reducing the risk of MLV-induced leukemia (Emery, 2011).  
To obtain a more global picture of cellular homeostasis alterations upon viral integration events, Soto-
Girón et al. (2011) recently attempted at predicting the changes due to HIV-1 integration in 
macrophages, using protein networks interacting directly with HIV-1 or indirectly through regulatory 
pathways (Balakrishnan et al., 2009, Schroder et al., 2002). They selected a few genes targeted by 
retroviral integration and compared the interactome of these gene products between non-infected and 
HIV-1 infected macrophages. By computational analysis, they showed that integration in 5 selected 
genes induced profound alteration of the global transcription network (Soto-Giron and Garcia-Vallejo, 
2012). Another illustration of cell homeostasis deregulation upon viral integration, leading to tumor 
development, resides in HBV infected cells, where multiple pathways involved in cell cycle are 
deregulated, including Wnt/β-catenin signaling, Ras/MAPK, PTEN/Akt, p14ARF/p53, and TGF-β 
pathways (Neuveut et al., 2010).  
Accumulation of genetic changes, chromosomal rearrangements, alterations of gene expression and 
cellular pathways as consequences of viral integration contribute incrementally to deregulate cell 
growth and induce tumor development when apoptosis is not involved. The database named DrVIS 
has recently been developed in order to report the association between viral integration sites and 
malignant diseases (Zhao et al., 2012). However, to date, the exact role of viral integration in cancer 
induction has not been fully clarified for many viruses.  
 
3.3. Viral persistence 
Many viruses can exist in a latent state, thus establishing a persistent infection. During this phase, 
viruses are transcriptionally silent, either completely or partially, allowing them to escape immune 
surveillance and establish viral reservoirs. Viral reservoirs represent a major obstacle for therapeutic 
strategies and virus eradication.  
A well-known example is illustrated by HIV-1, which can persist in resting memory CD4+ T cells 
(Chomont et al., 2009, Chun et al., 1997a, Chun et al., 1995, Chun et al., 1997b, Finzi et al., 1999, 
Finzi et al., 1997). Indeed, despite a very efficient combination therapy (highly active antiretroviral 
therapy, HAART), HIV-1 is not eliminated from the organism and rebounds upon HAART interruption. 
Although the mechanisms underlying virus reactivation, allowing the virus to exit a transcriptionally 
silent and latent state in favor of a productive state releasing infectious particles, is not yet completely 
understood, it is nevertheless obvious that this can only be achieved thanks to the presence of the 
integrated HIV-1 genome in the infected cell (Joos et al., 2008, Zhang et al., 2000). To date, it is 
thought that the only way to successful HIV-1 eradication resides in purging the viral reservoir, and 
that this could be achieved by reactivation of viral transcription from latently infected cells (Siliciano, 
2010). 
The molecular mechanisms promoting and maintaining in vivo latency of DNA and RNA viruses have 
not been completely elucidated and are still the focus of many investigations. In the case of HIV-1, 
three major players are currently involved in latency: (i) the availability of cellular transcription factors. 
Indeed, a current model implies that HIV-1 is transcriptionally active in activated infected T-cells, and 
that when the T-cells evolve to a resting memory state, many transcription factors become 
unavailable, thus silencing viral transcription (Coiras et al., 2009). Furthermore, epigenetic 
modifications implicating de novo methylation of the provirus and chromatin remodeling complexes 
may also contribute to the transcriptional silencing of the integrated retrovirus (Agbottah et al., 2006, 
Blazkova et al., 2009, Kauder et al., 2009, Mahmoudi et al., 2006, Treand et al., 2006), (ii) the level of 
the viral transactivator protein, Tat, which is responsible for efficient viral transcription, and (iii) the site 
of viral integration. Indeed, it has been shown that infected cells in a latent sate were characterized 
with proviruses in heterochromatin and centromeric regions (Jordan et al., 2003, Lewinski et al., 2005) 
and were found more often in sense orientation, leading to decreased viral transcription due to RNA 
interference (Shan et al., 2011).  
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Although herpes viruses establish latency via persistent episomes, it has been shown that HHV-6 
integration was also able to promote latency. Indeed, by a mechanism similar to HIV-1, HHV-6 
integration into telomeric heterochromatin, which are transcriptionally inactive regions may affect viral 
transcriptional activity, thereby favoring latency (Arbuckle et al., 2010, Arbuckle and Medveczky, 2011, 
Nacheva et al., 2008). This latent HHV-6 is non cytopathic as completely or partially silent. However, 
the reactivation of integrated HHV-6 by HDAC inhibitors, such as trichostatin-A, induces efficient viral 
production, as well as cytopathic effects (cell death and syncytium formation), which are eventually 
deleterious for the host (Arbuckle et al., 2010, Duelli and Lazebnik, 2007). 
 
3.4. Species evolution 
The integrating virus can be persistent not only at the level of the cell but also at the level of the 
organism. Indeed, viral integrationmay have a significant impact on the organism and its progeny if the 
virus succeeds in infecting the germ line. 
Retroviruses are the only viral group that has remnants in the form of integrated endogenous elements 
(ERV for Endogenous Retrovirus), accumulating over time in the human genome, and reaching to date 
approximately 8% of the total genome (Jern and Coffin, 2008). In humans, HERVs resemble to 
exogenous retroviruses, however, due to accumulated mutations, they lost their ability to replicate and 
can thus be considered as defective endogenous retroviruses. Even if retroviruses usually infect 
somatic cells, infection of a germ line cell can sometimes occur. In this way, HERVs were fixed in the 
human genome and could be transmitted through generations as a classical human gene driven by 
Mendelien’s rules. 
Integration of viral elements followed by endogenization can lead to profound consequences for the 
host, ultimately shaping its genome. The proof of concept of this is illustrated by syncytin genes that 
are expressed in trophoblasts. Syncytins display fusogenic activities that contribute to the formation of 
multinucleated syncytiotrophoblast cells, and are thus essential for placenta morphogenesis (Rawn 
and Cross, 2008). It has been shown that the syncytin-1 gene corresponds to the env gene of an 
endogenous retrovirus belonging to the HERV-W family that was fixed in the human genome 45 
million years ago (Mi et al., 2000). Similarly, another fusogenic protein named Syncytin-2 has been 
identified, corresponding to the env gene of HERV-FRD (Blaise et al., 2003). During primate evolution, 
these genes were conserved, and thus “captured” by the host as they provided a benefit for the host. 
In contrast, gag and pol genes accumulated inactivating mutations, leading to a replication-
incompetent retrovirus that could be otherwise detrimental to the host. 
As mentioned earlier, 8% of the human genome is composed of ERV remnants. Further investigations 
on these retroviral sequences should provide additional information about retroviral genes that are 
functional, like env-derived syncytins, and therefore likely to play a role in host cellular processes. 
  
General conclusions 
Integration of viral genome into host chromosomes results from (i) an essential step of life cycle, such 
as for retroviruses, or (ii) an incident, for some RNA viruses and DNA viruses. However, the high 
integration frequency of some DNA viruses (i.e HHV-6) and its role in establishing beneficial latency 
may challenge the view of incidental integration. Nevertheless, incidental or not, genome integration of 
DNA and RNA viruses have profound consequences for the host, including premature cell death and 
tumorigenesis, and that will in turn affect the rate of viral expression, thereby guiding the virus in a 
productive or latent cycle. In addition, viral integration events in the germ line may contribute to 
shaping the host genome, eventually providing selective advantages for the host, and contributing to 
species evolution.  
A better understanding of viral integration mechanisms, integration frequency, integration site selection 
and the impact of viral integration on the virus-associated disease outcome should help designing new 
strategies aiming at eradicating persistent viral infections, as well as improving virus-derived delivery 
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Figure 1 : Integration is a mandatory step of productive retroviral infection. A) Overview of the HIV-1 
life cyle. (see text for details). B) Viral integration mechanism is divided in three essential steps: 1) 3’ 
processing, 2) strand transfer, and 3) gap filling. IN: integrase. Filled red and green circles indicate 5’ 
phosphate and 3’OH ends respectively. Arrows indicate the actions performed by the host DNA repair 
machinery. Black arrows: cleavage of 5’ protruding viral ends. Grey arrows: gap filling of single-strand 
DNA. (see text for details). 
  
Figure 2: Retroviral integration site distribution. A) Host chromosomal preferences in integration site 
selection diverge among retroviral genera. () Gammaretroviruses (MLV) favors integration in 
promoters and in CpG islands, close to transcription start sites. () Lentiviruses (HIV) integrate 
preferentially into active transcription units. () Betaretroviruses (MMTV) integrate randomly. B) 
Schematic overview of the tethering model for HIV (left) and MLV (right). (see text for details). 
  
Figure 3: Integration site distribution of DNA viruses. A) Host chromosomal preferences in integration 
site selection of some DNA viruses. () MDV/HHV-6 viruses favor integration in telomeres. () AAV-2 
integrates preferentially at the AAVS1 site, () Ad integrates preferentially in gene loci, () EBV 
integrates in heterochromatin. B) Schematic overview of the integration mechanism potentially 
involved in some DNA viruses, AAV, EBV, KHSV and Ad (from left to right). TRS: terminal resolution 
site , RBE: Rep binding site, ITR: inverted terminal repeat, oriP: , HMGB2: high mobility group protein 
2, MeCP2: methyl-CpG-binding protein 2, MBD: methyl-CpG-binding domain, SYREC: symmetric 
recombinant, NHEJ: non homologous end joining repair machinery, HR: homologous recombination 
repair machinery. (see text for details). 
  
 Figure 4: Schematic overview of global consequences of viral integration events. Viral genome (red) 
insertion into gene exons (yellow) or introns (black line) eventually leads to gene disruption (left). Viral 
genome insertion into or close to promoters (blue) leads to an influence of viral enhancers on host 

















Table 1 Integration of vertebrate viruses.
 
 
  a      Family names of vertebrate viruses based on the classification from the International Committee on Taxonomy of Viruses 2011 
(www.ictvonline.org). 
  b      Integration occurring rarely in low-risk HPV types but more frequently for high-risk HPV types (HR-HPV) as HPV16 and HPV18 . 
  c      Integration only in the mosquito genome. 
  d      Integration observed only in the genome of arthropods. 
 *      Family containing at least one human pathogen (list of human viral pathogens can be found at http://viralzone.expasy.org/all_by_species). 
**     Observed in at least one paper but integration into the host genome for these viruses remains controversial.  
N.r    Not reported.  
 
              Class Family name
a
                       Virus examples of associated diseases Viral integration 
Linear double-stranded DNA Adenoviridae* Adenovirus serotype 12 (Ad12) Tumors in hamsters Rare 
 Asfaviridae African swine fever virus (ASFV) Lethal haemorraghic disease (domestic pigs), no disease for others 
species 
N.r 
 Iridoviridae Frog virus 3 (FV3) Death of frog embryos and larvae, no disease on adult frogs N.r 
 Herpesviridae* Epstein-Barr virus (EBV) Burkitt's lymphoma, Hodgkin's lymphoma and nasopharyngeal 
carcinoma 
Rare 
  Human herpesvirus 6 (HHV-6) Roseola Rare  
  Marek’s disease virus (MDV) Tumors (chicken and turkeys) Rare 
  Herpes simplex virus 1 (HSV1) Cold sores Rare 
  Varicella zoster virus (VZV) varicella, zoster Rare 
 Poxviridae* Vaccinia virus (VACV) vaccinia, cowpox N.r 
Circular double-stranded DNA Hepadnaviridae* Hepatitis B (HBV) Hepatocellular carcinoma Rare 
 Papillomaviridae* Human papillomavirus (HPV) Genital warts (HPV-6, HPV-11), cervival cancers (HPV-16, HPV-18) Rare
 b
   
 Polyomaviridae* Simian virus 40 (SV40) Tumors Rare 
Linear single-stranded DNA Parvoviridae* Adeno-associated virus serotype 2 (AAV-2) No pathology associated Rare 
Circular single-stranded DNA circoviridae Porcine circovirus-1 (PCV1) No pathology associated N.r 
     
Double-stranded RNA Birnaviridae Infectious pancreatic necrosis virus (IPNV) Pancreatic necrosis (fish) N.r 
  Infectious bursal disease virus (IBDV) Immunosuppression and mortality (young chickens) N.r 
  Drosophila X virus (DXV) Anoxia sensitivity and death (inoculated fly) N.r 
 Reoviridae* Group A rotavirus (RVA) Harmless infection of the respiratory and digestive tracts, diarrhea  N.r 
  Bluetongue virus (BTV) Cyanosis of the tongue (sheep, goats, cattle and deer) N.r 
(+) single-stranded RNA Arteriviridae Equine arteritis virus (EAV) Oedema, depression, fever, conjunctivitis (horse) N.r 
 Astroviridae* Avastrovirus 1 (AstV-1) Gastroenteritis N.r 
 Caliciviridae* Norwalk virus (NV) Gastroenteritis N.r 
 Coronaviridae* Severe acute respiratory syndrome 
coronavirus (SARS-CoV) 
Respiratory disease (pulmonary fibrosis, osteoporosis, femoral 
necrosis) 
N.r 
 Flaviviridae* Hepatitis C virus (HCV) Cirrhosis, hepatocellular carcinoma Incidental ? **  
  Yellow fever virus (YFV) Flu-like symptoms, jaundice N.r 
  Cell Fusing Agent virus (CFAV) No pathology associated  Common 
 c
 
  Kamiti River virus (KRV) No pathology associated Common
 c
 
  Tick-borne encephalitis virus (TBEV) Meningitis, encephalitis Incidental ? ** 
 Nodaviridae Nodamura virus (NoV) No pathology associated N.r 
 Picornaviridae* Human enterovirus C (HEV-C) Poliomyelitis N.r 
  Hepatitis A virus (HAV) Liver inflammation, hepatitis (no chronic infection) N.r 
  Foot-and-mouth disease virus (FMDV) High fever, myocarditis, death (newborn animals) N.r 
 Retroviridae* Human immunodeficience virus 1 (HIV-1) AIDS Mandatory 
  Murine Leukemia Virus (MLV) tumors Mandatory 
  Mouse Mammary Tumor Virus (MMTV) tumors Mandatory 
 Togaviridae* Sindbis virus (SINV) Sindbis fever, polyarthritis Incidental ? ** 
  Rubella virus (RUBV) Rubella N.r 
(-) single-stranded RNA Arenaviridae* Lymphocytic choriomeningitis virus (LCMV) Encephalitis, meningoencephalitis and pregnancy-related infection: 
congenital hydrocephalus, chorioretinitis, and mental retardation 
Incidental 
 Bornaviridae Borna disease virus (BDV) Proventricular dilatation disease (pet birds) Incidental 
 Bunyaviridae* Rift Valley fever virus (RVFV) Fever, hemorrhagic fever syndrome (< 2%), meningoencephalitis (< 
2%) 
Incidental 
 Filoviridae* Zaire ebolavirus (EBOV) Hemorrhagic fever Incidental 
 Orthomyxoviridae* Influenza A virus Fever, headache, cough, nasal congestion N.r 
  Influenza B virus Fever, headache, cough, nasal congestion N.r 
  Influenza C virus Fever, headache, cough, nasal congestion N.r 
 Paramyxoviridae* Measles virus Rubeola incidental 
  Sendai virus (SeV) Respiratory tract infection N.r 
  Hendra virus (HeV) Fever, headache and drowsiness N.r 
 Rhabdoviridae* Rabies virus (RABV) Malaise, fever, depression, respiratory insufficiency, death Incidental
 d
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